Subject Index to Volume 71

A

Acetylcholine
calcitonin gene-related peptide and, in striated muscle, 700–701
effect on early embryonic heart, 82
luteinizing hormone-releasing hormone and, in frog sympathetic ganglia, 701–702
somatostatin and, in parasympathetic control of toad heart, 700
vasoactive intestinal peptide and, in vertebrate salivary glands, 702–703
***N*-Acetylglucosamine nucleoporins,** *O*-linked
in nuclear pore complex, 914–915
in nuclear protein transport, 925–926
Acid-base balance, collecting duct acid-base transport, 272
ACTH. *See* Adrenocorticotropic hormone
Action potentials
arrhythmic, in early embryonic heart, 67
propagation, in early embryonic heart, 70–77
Active avoidance, dopaminergic transmission and, 160
Acyl-coenzyme A:retinol acyltransferase, in intestinal esterification of retinol, 957
Adaptation physiology, 1136. *See also* Hypoxic environment, physiological adaptation to
Adenohypophysial hormones. *See* Pituitary hormones, anterior
Adenosine
intrarenal artery infusion, reflex effects on cardiovascular system, 670–671
intrarenal artery injection, renorenal reflexes and, 674–675
Adenosine 3′,5′-cyclic monophosphate (cAMP)
accumulation in brain, histamine and, 16–17
calcium-regulated parathyroid hormone release and, 390
chloride conductance of mitochondria-rich cell and, 250–251
fetal lung liquid reabsorption and, 1003
in muscle tissue culture, 552
parathyroid hormone release by nonionic secretagogues and, 390
skeletal muscle adaptation to aerobic training and, 551–552
Adenosine triphosphate
coexistence with transmitters in adrenal gland and neuronal vesicles, 687
in cotransmission at vas deferens, 697–698
as cotransmitter at peripheral adrenergically innervated smooth muscle and striated muscle, 687–688
depletion, muscle fatigue during exercise and, 542
induction of conductance in macrophages, 782
Adenylate cyclase, activation, histamine H_2 receptors and, 18–19
Adhesion proteins, glycosaminoglycan interactions, 513–514
Adipose tissue
brown, energy requirement of sodium-potassium transport, 741
white, energy requirement of sodium-potassium transport, 741
Adipsia, mesocorticolimbic dopaminergic neuron lesions and, 159–160
β-Adrenergic agonists, fetal lung liquid reabsorption and, 1002
Adrenocorticotropic hormone (ACTH)
localization, processing, and extra-adrenal effects, 1023–1024
neurotrophic qualities. *See* Neurotrophic factors, ACTH/MSH peptides
peptide fragments, 1024
release, oxytocin and, 335–336
secretion, histaminergic neurons and, 24–25
Age/aging
cardiovascular response to stress and, 324
cellular, calpain-mediated proteolysis in erythrocytes in, 831
dopaminergic transmission reactivity, 205–208
Aggressive behavior, control, histaminergic neurons in, 29
Airway epithelia, ion transport
fetal, 1008–1009
postnatal changes, 1009–1010
Airways, conducting
antigen-presenting cells in, 1122–1124
immunologic components, 1118–1124. *See also* Respiratory immunity
integrated immunologic function, 1124
topography, 1117–1118
Aldose reductase, 1087–1088
in renal cells, 1089
osmotically induced changes in, 1089–1091
Alkalinization, in excitation-contraction coupling, 891–892
Altitude, high
developmental adaptation to, 1155–1157
growth and development in animals, experimental studies, 1156–1157
human growth at, 1155
loss of adaptation to, 1157–1158
physiological adaptation to
developmental adaptation, 1155–1157
embryonic adaptation, 1150–1155
oxygen transport in mammals and birds, 1135–1160. *See also* Hypoxic environment; Oxygen transport
respiratory function in humans, development of, 1155–1156
Alveolar space
immune interactions in, 1125–1128
immune responsiveness in, 1128–1130
Amacrine cells, retinal, 456–462
Amblyopia, strabismic, neural basis, 590–591
Amiloride, chloride transport and, 258–259
Amine precursor uptake and decarboxylation (APUD) cells, cotransmission and, 695
γ-Aminobutyric acid, coexistence with other bioactive substances in neurons, 690–691
Amphibian skin
cation transport systems, 237
chloride transport, 235–275
functional organization, 236–239
ionic pathways of mitochondria-rich cells, 245–251
mathematical models of epithelium, 252–263
mitochondria-rich cells, 237–238
paracellular ion permeabilities, 251–252
principal cells of epidermis, 237–238
transepithelial ionic currents and their voltage dependence, 239–245
transport models, 237
epidermal cell types, 236
functional organization, 236–239
proton excretion, 264
Amygdala, dopaminergic transmission, 168–169
Analgesia, oxytocin and, 340
Anesthetics, local, skeletal muscle excitation-contraction coupling and, 880–881

0031-9333/91 $1.50 Copyright © 1991 the American Physiological Society

Angiogenesis, in neoplasia, glycosaminoglycans and, 515–518
Anions, channel-mediated apical sodium entry in epithelia and, 437
Annulate lamellae, 916–917
Antidiuretic hormone. *See also* Vasopressin
in diuretic response to atrial distension, 632–633
Antigen-presenting cells, in airways and interstitium, 1122–1124
Antipyretics. *See also* Cryogens
endogenous, in urine, 112–114
Antithrombin III, 486–489
Aortic stenosis, cardiac reflexes in, 647
Aphagia, mesocorticolimbic dopaminergic neuron lesions and, 159–160
Aplysia,, bag cell peptides, 707–708
Apolipoprotein B-100, glycosaminoglycan interactions, 490–492
Apolipoprotein E, glycosaminoglycan interactions, 492–493
APUD. *See* Amine precursor uptake and decarboxylation (APUD) cells
Arginine vasopressin, fever and, 110–111
Arousal, histaminergic neurons in, 27–29
Arrhythmia
arrhythmic action potentials, in early embryonic heart, 67
cardiac reflexes in, 647
Atherosclerosis, glycosaminoglycans and, 493–494
Atrium(a)
distension. *See also* Cardiac reflexes, atrial receptor stimulation and
heart rate and, 627–629
kidney function and, 630–634
sodium excretion and, 632
urine flow and, 631–632
vascular response to, 629–630
myelinated afferent nerve fibers attached to, 619–621
nonmyelinated vagal afferent nerves arising from, 621
receptors. *See* Cardiac receptors
Auditory cortex, visual deprivation and, 596
Aversion, control, histaminergic neurons in, 30

B

B cells, ion channels in, 799–804
calcium conductance, 800–801
chloride conductance, 801–802
physiological relevance, 802–804
potassium conductances, 799–800
sodium conductance, 801
Baroreceptor reflex
cardiogenic reflexes and, 641–643
response to stress, 317–318
Behavior
control, histaminergic neurons in, 29–30
dopaminergic neuron activation and, 172–185
adaptation, adjunctive behavior, and coping, 177–179
adaptive responses, 176–180
consummatory and environment-related responses, 176–177
lateralization of functions, 180–185
locomotor hyperactivity and stereotypy, 172–176
dopaminergic transmission and, 167
learned, oxytocin and, 345–347
maternal, oxytocin and, 343–344
oxytocin and, 341–347
reinforced conditioning. *See* Reinforcement
sexual, oxytocin and, 342–343
spontaneous, oxytocin and, 341–345
type A, cardiovascular response to stress, 311–312
behavioral challenge and, 323
type B, cardiovascular response to stress, 311–312
behavioral challenge and, 323
Behavioral deficits, dopaminergic neuron lesions and, 209
Behavioral sensitization, dopaminergic transmission and, 165, 185–191
Betaine, 1097–1100
accumulation in renal cells, osmotic regulation of, 1098–1100
metabolism and transport, 1097–1098
Bipolar cells, retinal, 454–456
Bladder. *See* Urinary bladder
Blood, oxygen transport, physiological adaptation to high altitudes, 1142–1148
Blood-cerebrospinal fluid barrier, passage of oxytocin, 347
Blood flow
cerebral, control, histaminergic neurons in, 26
coronary, exercise training and, 573
high altitude and, 1144–1145
muscle, exercise training and, 573–574
renal, stress and, 313–316
Blood pressure, possible analogies between plasma retinol homeostasis and blood pressure regulation, 982
Body temperature
circadian rhythm, 116
exercise and, 114–115
postovulatory rise in, 115–116
stress and, 117
Bradykinin
intrarenal artery infusion, reflex effects on cardiovascular system, 670–671
intrarenal artery injection, renorenal reflexes and, 674–675
Brain
blood flow, control, histaminergic neurons in, 26
cotransmission. *See* Cotransmission
energy requirement of calcium transport, 747–748
energy requirement of sodium-potassium transport, 737–738
histamine metabolism, 2–8
biosynthesis, 2–4
inactivation, 6–7
release, 5–6
storage, 4–5
turnover, 7–8
histamine receptors, 14–22
H_1 receptors, 14–18
H_2 receptors, 18–20
H_3 receptors, 20–22
histaminergic transmission, 1–30. *See also* Histaminergic neurons
disposition of histaminergic neuronal pathways, 8–13
mast cells in, 13–14
target areas for oxytocin and action mechanisms, 347–353
brain stem, 352
does oxytocin act via other neurotransmitters, 350–351
electrophysiological effects of oxytocin at cellular levels, 351–353
hypothalamus and forebrain, 353
limbic areas, 352
origin of centrally acting oxytocin, 347–350
sympathetic preganglionic and ganglionic neurons, 351
Brain function, dopaminergic network and, 171–209. *See also* Dopaminergic network (neurons)
Brain stem
afferent renal nerve fiber projections, 666–667
target areas for oxytocin and action mechanisms, 352
Brain stimulation reward, dopaminergic transmission and, 195–198

C

Cadmium, extracellular, cellular recognition of changes in, 402
Caffeine, skeletal muscle excitation-contraction coupling and, 880
Calcitonin gene-related peptide

acetylcholine and, in striated muscle, 700–701
tachykinins and, in mammalian heart and other peripheral sites, 698–700
Calcium
activation of cation conductance in neutrophils, 786
apical sodium entry in epithelia and, 434–436
balance. *See* Calcium homeostasis
cytosolic, calcium-regulated parathyroid hormone release and, 390–392
extracellular, 372
cellular recognition of changes in. *See* Calcium sensing
modulation of function of other cell types, 399–400
parathyroid hormone regulation, 374–393. *See also* Parathyroid hormone secretion
intracellular, 372
rhythmicity of embryonic heart and, 67
skeletal muscle excitation-contraction coupling and. *See* Excitation-contraction coupling
Calcium agonists, skeletal muscle excitation-contraction coupling and, 879–880
Calcium antagonists, skeletal muscle excitation-contraction coupling and, 876–877
Calcium channel blockers, skeletal muscle excitation-contraction coupling and, 881–882
Calcium channels
in B cells, 800–801
kinetic homologies to other ion channels, 1075–1076
structural homologies to other ion channels, 1075
in T cells, 794–795
response to mitogens and, 797–798
Calcium homeostasis
hormonal control, 372–374
ischemia or hypoxia and, 761–762
parathyroid glands in, 374
Calcium pump, plasma membrane, 129–146
activation
calmodulin, 132–133
kinase-mediated phosphorylation, 134
lipids, 133
proteins, 134
proteolysis, 133–134
calmodulin stimulation, 132–133
discovery and general properties, 130–132
of eucaryotic cells, 135–137
hormonal regulation, 146
inhibitors, 134–135
pathological alterations, 146
primary structure and functional domains, 142–146
purified pump
isolation, reconstitution and properties, 137–140
proteolysis of, 140–142
Calcium sensing, 393–400
C cells, 395–396
kidney cells, 396–398
osteoclasts, 398
parathyroid cell, polyfunctional regulator of second messengers and other intracellular regulatory mechanisms, 389–390
placental cells, 398–399
subcompartments within extracellular space that differ in calcium concentration, 394–395
Calcium transport. *See also* Cation transport
energy requirement of, 741–748
Calmodulin, stimulation of plasma membrane calcium pump, 132–133
Calpain system, 813–837
autoproteolytic modification of CANP in vitro, 819–821
functional consequences of, 820
other proposed regulatory mechanisms, 820–821
structural modifications of enzyme subunits, 819–820
biochemistry and in vitro studies, 836
in calcium regulation of intracellular protein degradation, 826–828
characterization of and comparisons between CANP-I and CANP-II, 815–819
catalytic properties, 817
cDNA and amino acid sequences, 815–817
substrate specificity, 817–819
endogenous regulatory proteins, 821–823
inhibitory protein (calpastatin), 821–823
stimulatory protein, 823
identification of calcium-activated neutral proteases, 814
physiological functions of calcium-dependent proteolysis, 823–836
physiological roles
biochemical determination, 823–825
proposed, overview of, 825–826
physiology of, 836–837
in platelet aggregation, 829–831
proteolysis in erythrocytes in cellular aging, hypertension, and membrane fusion, 831–833
in proteolysis of protein kinase C, 835–836
neutrophil activation and, 835–836
platelet activation and, 836
in proteolytic modification of neuronal submembrane skeleton, role in long-term potentiation, 833–835
in proteolytic modification or degradation of receptors, enzymes, and cytoskeletal proteins, 828–829
purification of calcium-activated neutral proteases, 814–815
summary of current knowledge of biochemistry and future directions, 823
Calpastatin, 821–823
cloning and expression of cDNA, 822–823
isolation and analysis, 821–822
cAMP. *See* Adenosine 3',5'-cyclic monophosphate
Capillary proliferation, skeletal muscle adaptation to aerobic training, 559
Cardiac myocytes, 413–424
contractile responses in active cardiac myocytes, 418–420
active force development in intact cells, 419–420
displacement recordings in unattached stimulated cells, 420
force measurements in skinned myocytes, 418–419
indexes of contractility, 420–424
shortening, 420–421
shortening related to Frank-Starling relation, 421–424
isolated adult myocyte preparation, development of, 414
mechanical properties, 414–420
attachment procedures, 414–415
comparative elastic properties of skeletal and cardiac cells, 415
contractile responses in active cardiac myocytes, 418–420
passive, 415–418
relation of cellular to tissue elasticity in cardiac muscle, 415–416
sarcomere uniformity, 417–418
structural basis of cardiac myocyte resting tension, 416–417
metabolism, exercise training and, 574
oxidative phosphorylation, exercise training and, 574
shortening related to Frank-Starling relation, 421–424
buckling of thin filaments, 422
compressed cross bridges, 422
contractility related to diastolic length, 423–424
length-dependent activation, 423
restoring forces, 421–422
shortening deactivation, 423
thin filament interference of cross-bridge attachment, 421
Cardiac receptors
afferent cardiac sympathetic nerves, 624–625
chemical stimulation of, 643–644
electrical stimulation of, 643
mechanical stimulation of, 644–645
response to activation of, 643–645

atrial
discharge patterns from, 619–620
do types A, B, and intermediate discharge patterns arise from different receptors, 620
factors influencing discharge, 620–621
myelinated nerves attached to, 619–621
negative pressure breathing and, 630–631
responses to stimulation, 625–634
tamponade and, 631
techniques to stimulate, 625–627
water immersion and, 631
ultrastructure
afferent innervation of heart, 618–619
complex unencapsulated endings, 619
end net, 619
ventricular, 621–624
aortic occlusion and, 636
are mechanosensitive and chemosensitive receptors different, 624
chemical stimulation, 623, 636–638
interruption of cardiac nerves and, 635–636
mechanical stimulation, 621–623
mechanical stimulation of left ventricular receptors, 638–640
responses to stimulation of, 634–643
right ventricular distension, 640–641
stimulation of cardiac afferent nerves and, 635
Cardiac reflexes, 617–649. *See also* Cardiac receptors
afferent discharges in nerves from heart, 619–625
afferent activity in sympathetic nerves, 624–625
afferent activity in vagal nerves ending in ventricles, 621–624
myelinated nerves attached to atrial receptors, 619–621
nonmyelinated vagal afferent nerves arising from atria, 621
in aortic stenosis, 647
atrial receptor stimulation and, 625–634
kidney function and, 630–634
reflex effects on heart, 627–629
vascular responses, 629–630
in disease, 645–647
in heart failure, 647
in myocardial ischemia and infarction, 645–647
depressor reflexes, 645–646
pressor responses, 646
physiological and pathophysiological importance, 647–649
problems in assessing importance of, 647–648
reflexes arising from stimulation of atrial receptors attached to myelinated vagal fibers, 648
role of nonmyelinated vagal aggerents from atria, 648
role of ventricular chemosensitive endings, 649
sympathetic cardiac afferent nerves, 649
ventricular mechanoreceptors attached to vagal fibers, 648–649
in tachyarrhythmias, 647
ultrastructure of cardiac receptors, 618–619. *See also* Cardiac receptors
ventricular receptor stimulation and, 634–643
aortic occlusion, 636
changes in coronary vascular pressure, 641
chemical stimulation, 636–638
interruption of cardiac nerves, 635–636
mechanical stimulation of left ventricular receptors, 638–640
procedures likely to change input from ventricular receptors other than by application of localized stimuli, 635–636
response to changes in stimuli to both ventricular receptors and arterial baroreceptors, 641–643
right ventricular distension, 640–641
stimulation of cardiac afferent nerves, 635
Cardiovascular system
molecular and cellular adaptation to exercise, 566–574
adaptations that affect cardiac and peripheral blood flow, 573–574
adaptations that affect cardiac myocyte metabolism, 574
adaptations that affect cardiac output, 566–573
ontogeny of electrical activity and related functional organization during early heart devlopment, 53–83. *See also* Heart, early embryonic
oxytocin and, 337–338
reflex effects of changes in afferent renal nerve activity, 668–672
regulation, histaminergic neurons in, 25–26
response to stress, 305–326
age and, 324
baroreceptor reflex responses, 317–318
behavior pattern, 311–312
brain peptides and neuroregulation, 321–322
cardiac responses, 313
cardiovascular reactivity to behavioral challenge, 323
cold pressor test, 309–311
diet and, 325
epinephrine responses, 318–319
family history and, 326
historical perspective, 305–313
laboratory studies, 307–311
mental stress, 307–309
methodological issues in measuring behavioral responses, 323–324
methodological issues in measuring neuroendocrine responses, 322–323
modifiers, 324–326
neuroanatomic studies, 306–307
neuroendocrine responses, 318–323
norepinephrine responses, 318
physical conditioning and, 325–326
pituitary-adrenal responses, 319–321
race and, 324–325
renal blood flow, 313–316
sex and, 324
stress hormones, 305–306
sympathetic nerve activity, 316–317
Catecholamines
calcium transport and, 752–757
heart, 752–753
liver, 753
skeletal muscle, 753
effect on early embryonic heart, 82
sensitivity to, exercise training and, 572
sodium-potassium transport and, 749
Cation transport
basal metabolic rate and thermogenesis and, 757–759
cold adaptation, 758
endothermia, 758–759
sodium-potassium pump-dependent oxygen uptake in intact organism, 757–758
energy requirement of calcium transport, 741–748
brain, 747–748
heart, 745–747
liver, 748
skeletal muscle, 742–745
energy requirement of sodium-potassium transport, 734–741
brain, 737–738
brown adipose tissue, 741
erythrocytes, 740–741
heart, 736–737
intestine and smooth muscle, 741
kidney, 740
liver, 738–740
skeletal muscle, 734–736
white adipose tissue, 741
hormonal regulation of, 749–757

calcium transport, 752–757
sodium-potassium transport, 749–752
ischemia and oxygen paradox and, 761–763
calcium homeostasis during ischemia or hypoxia, 761–762
reperfusion injury, 762–763
malignant hyperthermia and, 759–761
pathological conditions, 759–763
significance in control of energy metabolism and thermogenesis, 733–764
C-cells, calcium sensing, 395–396
cDNA. *See* Deoxyribonucleic acid, complementary
Cellular biology, covalent control in, 285–303. *See also* Covalent modification
Cerebrospinal fluid, oxytocin in, passage into brain, 348
Cerebrovascular system, oxytocin and, 338
cGMP. *See* Guanosine 3′,5′-cyclic monophosphate
Chaotropic ions, skeletal muscle excitation-contraction coupling and, 875–876
Chloride, extracellular, cellular recognition of changes in, 401
Chloride channels
in B cells, 801–802
in macrophages, 781–782
in neutrophils, 786
in T cells, 795–796
Chloride transport
across fetal airway epithelia, 1008–1009
in amphibian skin, 235–266
active transport, 263–266
chloride-bicarbonate and chloride-chloride exchange, 263–264
chloride current rectification, 239
energy requirements of chloride currents, 240–241
features of steady-state current-voltage relationship, 239–241
mathematical models of epithelium, 252–263
mitochondria-rich cells, 245–251
mitochondria-rich cells and principal cell compartment behave as noncouped units, 239
paracellular ion permeabilities, 251–252
principal cells, 237–238, 241–245
proton transport, 264–265
time dependence of chloride currents, 241
transepithelial ionic currents and their voltage dependence, 239–245
transport models, 237
in collecting duct of vertebrate kidney, 271–273
in high-resistance heterocellular epithelia, 235–275
mathematical models of epithelium, 252–263
cell coupling via extracellular current loops, 263
current-voltage relations, 259–261
description of equations, 252–254
effects of amiloride, 258–259
effects of ouabain, 256–257
reconstructed voltage-clamp currents, 261–263
short- and open-circuit conditions, 254–255
testing model predictions, 255–261
in vertebrate urinary bladder, 266–271
junctional membrane permeabilities, 270–271
mitochondria-rich cells, 269–270
principal cells, 267–269
Chondroitin sulfate. *See* Glycosaminoglycan(s)
Chorioallantoic membrane, of high-altitude birds, 1153–1154
Chromatin, relation of nuclear pore complex to, 912–913
Chylomicron(s)
metabolism, use of chylomicron retinyl esters in study of, 959–960
plasma metabolism of, 958–959
Chylomicron retinyl esters
extrahepatic clearance of, 960–961
processing by liver parenchymal cells, 962–963
in study of chylomicron metabolism, 959–960
uptake by liver parenchymal cells, 962
Circadian rhythm, dopaminergic transmission reactivity and, 204–205
Circulation
cerebral, control, histaminergic neurons in, 26
pulmonary, oxygen transport at high altitudes and, 1140–1142
Coexistence. *See* Cotransmission
Cognitive processes, dopaminergic transmission and, 165–166
Cold adaptation, cation transport and, 758
Cold pressor test, cardiovascular response to stress, 309–311
Contractility, active cardiac myocytes, 418–420
indexes of, 420–424
Coronary artery(ies)
occlusion, cardiac reflexes in, 645–647
pressure changes, cardiac reflexes and, 641
Cortical neuronal system, mesocortical dopaminergic transmission and, 162–166. *See also* Dopaminergic network (neurons)
Corticosteroids, in diuretic response to atrial distension, 633–634
Corticotropin-releasing factor
neurotrophic effects, 1032
vasopressin release and, 708–709
Corticotropin-releasing hormone, release, oxytocin and, 335–336
Cortisol, gestational pattern of plasma levels, 1003–1004
Cotransmission, 683–712
chemical modification, 685–686
definitions and basic concepts, 684–686
evolutionary considerations, 694–696
APUD cell concept, 695
common origin of nervous and endocrine systems, 695
origin of nervous system from endocrine cells, 695–696
segregation of receptors, 694
functions, 709–711
addition, 710
division, 710
higher mathematics, 711
mutiplication, 710
subtraction, 711
functions of cotransmitters, 696–709
acetylcholine and somatostatin in parasympathetic control of toad heart, 700
bag cell peptides in *Aplysia*, 707–708
calcitonin gene-related peptide and acetylcholine in striated muscle, 700–701
calcitonin gene-related peptide and tachykinins in mammalian heart and other peripheral sites, 698–700
corticotropin-releasing factor and vasopressin release from median eminence, 708–709
cotransmitters at invertebrate muscle, 703–707
cotransmitters at vertebrate muscle, 697–701
luteinizing hormone-releasing hormone and acetylcholine in frog sympathetic ganglia, 701–702
neuropeptide Y, adenosine triphosphate, and norepinephrine in vas deferens, 697–698
oxytocin and vasopressin, 708
purines at vertebrate neuromuscular junctions, 701
smooth muscle, 697–700
striated muscle, 700–701
vasoactive intestinal peptide and acetylcholine in vertebrate salivary glands, 702–703
vasopressin and oxytocin in posterior pituitary, 709
historical considerations, 686–689
adenosine triphosphate as cotransmitter at peripheral adrenergically innervated smooth muscle and striated muscle, 687–688
coexistence of adenosine triphosphate with transmitters in adrenal gland and neuronal vesicles, 687

early speculations and anomalous findings, 686–687
invertebrate studies, 688
peptides, 688–689
model of transmitter function, 691–694
presynaptic regulation and differential release, 692–694
receptor-receptor interaction, 692
at muscle, functional meaning, 707
novel sources of messenger molecules, 685
selected examples of patterns of coexistence, 690–691
γ-aminobutyric acid, 690–691
neuropeptide Y, 691
survey of coexistence, 689–691
are there rules of coexistence, 689–690
peptide transport, 689
selected examples of patterns of coexistence, 690–691
synthesis from propeptide, 689
why are there multiple transmitters, 694–709
evolutionary considerations, 694–696

Covalent modification
beyond the simplicity of phosphorylase, 298–302
covalent interactions, 298–299
multiple intermediates for glycogen synthase, 301–302
phosphorylase kinase reaction progression, 299–301
in cellular biology, 285–287
classification of complexity
beyond the simplicity of phosphorylase, 298–302
phosphorylase as a simple(?) model, 289–298
modes of activation by, 302–303
assessing the rate-limiting step, 302–303
classification of activity changes, 302
regulating covalent modification, 302
regulation of catalysis and modular binding, 302
phosphorylase as a simple(?) model, 289–298
changes in activity with reaction progression, 291
defining activity, 293
formation and properties of hybrid phosphorylase, 291–293
pathways of intermediates during phosphorylation and dephosphorylation, 294–295
physiological implications of partially phosphorylated intermediates, 293–294
reaction progression, 289–290
comparison with allosteric theory, 296–298
structure of phosphorylation sites, 295–296
physiological rationale for complexity, 287–289
on/off coordination of reciprocal pathways, 287–288
regulation at rate-determining steps, 287
regulation of multisubstrate enzymes, 288–289
reversibility as criterion of suitable covalent control mechanism, 286–287

Cryogens, fever and, 93, 109–114

Cytokines, fever and, 103–109

Cytoskeletal proteins, proteolytic modification or degradation, calpain system in, 828–829

Cytotoxicity, T cell, ion channels and, 798

D

Deoxyribonucleic acid (DNA)
in compensatory overload-induced hypertrophy, 564
complementary (cDNA)
calpastatin, 822
sequence of calcium-activated neutral proteases, 815–817

Dermatan sulfate. *See* Glycosaminoglycan(s)

Diet, cardiovascular response to stress and, 325

Diuresis, atrial receptor stimulation and, 630–632
antidiuretic hormone in, 632–633
corticosteroids in, 633–634
other humoral agents in, 633–634
renal nerves in, 634
renin in, 633

DNA. *See* Deoxyribonucleic acid

Dopamine code, 171–172

Dopaminergic network (neurons)
behavioral correlates of activation of dopaminergic neurons, 172–185
adaptation, adjunctive behaviors, and coping, 177–179
adaptive responses, 176–180
brain asymmetry, dopaminergic lateralization, and individuality, 183–185
consummatory and environment-oriented responses, 176–177
lateralization of functions, 180–185
analysis, 181–183
locomotor hyperactivity and stereotypy, 172–176
problems of individual differences, 179–180
spontaneous and induced dopaminergic asymmetry, 180–181
brain functioning and, 171–209
behavioral correlates of activation of dopaminergic neurons, 172–185
dopamine code, 171–172
dopaminergic neuroregulation, 171–172
intrinsic variables contributing to individual differences in dopaminergic transmission reactivity, 204–209
plasticity at level of dopaminergic transmission, 185–195
reinforcement and reward, 195–204
brain stimulation reward, 196–198
controversies and reevaluation, 197–198
self-stimulation, 196–197
cortical neuronal system
increased reactivity of cortical dopaminergic neurons during arousal, environmental challenges and stressful situations, 163–165
inhibitory effects of mesocortical dopaminergic neurons, 162–163
drug self-administration and drug dependence, 198–202
dopamine receptor blockade and, 199–200
dopamine transmission and opiate self-administration, 201
holistic approach to, 200–201
intracranial self-administration, 201–202
questions relating to drug self-administration phenomenon, 198–199
inhibitory effects of mesocortical dopaminergic neurons, 162–163
intrinsic variables contributing to individual differences in dopaminergic transmission reactivity, 204–209
age-related changes, 205–208
genetic differences, 205
variations with circadian rhythm, 204–205
mesoamygdaloid transmission, 168–169
mesocortical dopaminergic transmission
cognitive processes and, 165–166
inhibitory effects on cortical neuronal system and dopaminergic network, 162–163
sensitization phenomenon, 165
in stress, anxiety and integrative functions, 164–165
mesocorticolimbic
active avoidance and, 160
aphagia and adipsia and, 159–160
functional and regulatory roles, 155–210
functional approach to, difficulties, 156–157
functional characterization of, 158–171
6-hydroxydopamine lesions, 158–159
learning processes and, 160
lesions, behavioral deficits and, 209
locomotor activity and, 159

mesoaccumbens dopaminergic transmission and ventral striatum system, 161–162
mesoamygdaloid transmission, 168–169
mesocortical dopaminergic transmission and cortical neuronal system, 162–166
mesohabenular projection, 169–170
mesohippocampal transmission, 169
mesoseptal dopaminergic transmission, 166–168
regulatory role of dopaminergic neurons, 209–210
sensorimotor integration and motivation, 160
septal system, 166–168
septohippocampal neuronal system, 166–168
ventral mesencephalic tegmentum and dopaminergic cell bodies, 158–160
mesocorticoprefrontal neurons, stressful situations and, 163–164
mesohabenular projection, 169–170
mesohippocampal transmission, 169
mesoseptal dopaminergic transmission, 166–168
behavior and, 167
functional consequences of selective lesions, 167–168
spatial memory and, 167–168
necessity in general economy of brain, 210
ontogenesis, 206–208
plasticity at level of dopaminergic transmission, 185–195
acquisition of conditioned reinforcement, 192–194
behavioral sensitivation after drug administration, 185–191
conditioned responses and latent inhibition, 191–195
dopaminergic transmission blockade and latent inhibition, 194–195
drugs acting on dopaminergic neurons as unconditioned stimuli, 191–192
tolerance, habituation, and other compensatory mechanisms, 195
reinforcement and reward, 195–204
brain stimulation reward, 195–198
drug self-administration and drug dependence, 198–202
meaning of a search for reward pathways, 195–196
place conditioning as technique for determining role of dopaminergic transmission in reinforcement processes, 202–204
ventral mesencephalic tegmentum, 158–160
lesions, 158–160
medial ventral mesencephalon as anatomofunctional entity, 158
ventral striatum, 161–162
Drinking, control, histaminergic neurons in, 29
Drug(s), histamine turnover and, 8
Drug addiction/dependence
dopaminergic transmission and, 198–202
dopamine receptor blockade and, 199–200
drug self-administration phenomenon, 198–199
opiate self-administration, 201
holistic approach to drug self-administration, 200–201
intracranial drug self-administration, 201–202
oxytocin and, 346–347
Dyes, voltage-sensitive, 55–57

E

Eating, control, histaminergic neurons in, 29
Electrical activity, in early embryonic heart
basic characteristics of optical signals, 60–61
early events in development of, 62–64
ionic properties, 64–66
onset of electrical activity in perfused cardiac primordia, 61–62
optical indications of, 60–66
optical methods for monitoring, 53–83
applications to cardiac muscle, 58–59
optical recording system, 57–58
voltage-sensitive dyes, 55–57
resting potential, 66
Embryo, physiological adaptation to high altitude, 1150–1155
birds, 1152–1155
mammals, 1150–1152
Emesis, histaminergic neurons in, 27
Endothermia, cation transport and, 758–759
Energy metabolism, cation transport in, 733–764. *See also* Cation transport
energy requirement of calcium transport, 741–748
energy requirement of sodium-potassium transport, 734–741
Enzyme(s). *See also specific enzymes*
glycolytic, skeletal muscle adaptation to aerobic training, 553–555
lipolytic, glycosaminoglycan interactions, 498–500
proteolytic modification or degradation, calpain system in, 828
Epidermal growth factor, fetal lung liquid secretion and, 1007
Epinephrine
fetal lung liquid reabsorption and, 1002–1006
gestational maturation of β-adrenergic effect, 1002–1003
mechanism of, 1004–1006
thyroid hormones and hydrocortisone in, 1003–1004
kinetics, stress and, 318–319
Epithelium(a)
airways. *See* Airway epithelia
apical sodium entry
carrier-mediated sodium entry, 433–434
intracellular calcium in, 436
channel-mediated sodium entry, 432–433
anion effects on, 437
intracellular calcium in, 434–436
expansion and reduction of functional apical membrane area, 438–440
feedback inhibition, 432–433
pharmacology of, 436–437
inhibition by extracellular sodium, 430–431
inhibition by intracellular sodium, 432–434
intracellular calcium in, 434–436
intrinsic regulation of, 429–440
regulation of apical membrane permeability to sodium by cell metabolism and pH, 437–438
self-inhibition, 430–431
pharmacology, 436–437
high-resistance heterocellular, chloride transport, 235–275. *See also* Chloride transport
Erythrocyte(s)
calcium pump. *See* Calcium pump, plasma membrane
energy requirement of sodium-potassium transport, 740–741
Erythropoiesis, high altitude and, 1143–1144
Erythropoietin, high altitude and, 1143–1144
Eucaryotic nucleus, three-dimensional structure, 934–935
Excitation-contraction coupling
calcium release: activation, 859–870
calcium transients, 859
calculation of flux, 860–863
charge movement and, 864–870
flux of, 860–864
kinetic comparisons of release and charge movement, 865
kinetics, 860
kinetics of release flux, 863–864
Q_γ and, 866–869
transmission delays, 860, 865–866
voltage dependence of, 863
voltage dependence of release and charge movement, 865

calcium release: inactivation, 870–873
inactivation and charge immobilization, 870–873
inactivation of contraction, 870
simple model of, 870–873
intracellular charge movements
charge movement in heart muscle, 885
comparative aspects, 883–885
sodium channel gating current, 883–885
intramembrane charge movement, 850–859
calcium release and, 864–870
charge 2 or Q_α, 857–858
cut fiber techniques and problems with, 851–853
description of charge movement, 853–858
identification of, 850–851
measurements in intact fibers, 851
optical signal associated with, 869
properties of charge 1, 855–856
Q_β and Q_γ, 856–857
mechanisms of transmission, 890–898
alkalinization, 891–892
calcium-induced calcium release, 892–894
electrical transmission, 890–891
inositol trisphosphate, 894–896
mechanical coupling, 896–897
sulfhydryl oxidation, 892
molecular studies, 885–890
identification of release channel protein, 886–887
identification of voltage sensor, 887–889
incorporation of sarcoplasmic reticulum and T-tubule membrane vesicles into lipid bilayers, 886
subcellular fractionation, 885–886
voltage sensor of, 849–898
caffeine and, 880
calcium agonists and, 879–880
calcium and, 873–875
calcium antagonists and, 876–877
chaotropic ions and, 875–876
ions and, 873–876
local anesthetics and, 880–881
metal ions and, 875
modifiers of, 873–883
modulated binding of drugs to, 877–879
modulation of, 882–883
molecular identification of, 887–889
pharmacology of, 876–882
release channel blockers and, 881–882
sulfhydryl oxidants and, 882
Exercise
adaptations to, significance of, 542
hyperthermia and, 114–115
physical conditioning, cardiovascular response to stress and, 325–326
single bout
glucose uptake and, 545–547
malonyl-coenzyme A and, 547
response of cellular processes in skeletal muscle to, 545–547
sarcoplasmic reticulum function and, 547
skeletal muscle fatigue during, 542–544
Exercise training
cardiac myocyte metabolism and, 574
cardiac output and, 566–573
chronotropic adaptations, 572–573
ejection fraction, 569–572
end-diastolic volume, 566–569
stroke volume adaptations, 566–572
cardiovascular adaptation to, 566–574
coronary blood flow and, 573
heart size and, 569–570
molecular and cellular adaptation of muscle to, 541–575
adaptations that affect cardiac output, 566–573
animal models mimicking human heavy-resistance training, 560–561
animal models of increased contractile activity that do not mimic human physical activity, 544–545
animal models that closely mimic human physical activity, 544
inferred sites for gene expression in, 566
capillary proliferation, 559
classification of models, 544–545
glycolytic enzymes, 553–555
hypertrophy in animal models not mimicking human physical activity, 561–564
increased contractile activity in tissue cultures of muscle cells, 545
lactate dehydrogenase, 555–556
mitochondria, 547–553
muscle/muscle cells in culture do not mimic human physical activity, 564–565
myoglobin concentration, 559–560
myosin isoform switching, 556–559
oxygen flux, 559–560
physiological significance, 541–544
repeated bouts of aerobic exercise, 547–560
repeated bouts of resistance exercise, 560–561
terminology, 545
muscle blood flow and, 573–574
Extracellular matrix, proteins, glycosaminoglycan interactions, 500–504

F

Family history, cardiovascular response to stress and, 326
Fatigue, skeletal muscle, exercise and. *See* Skeletal muscle
Feedback inhibition, apical sodium entry in epithelia, 432–433
pharmacology of, 436–437
Feeding, oxytocin and, 345
Fetus, lung liquid. *See* Lung liquid
Fever
adaptive function, 96–98
arginine vasopressin and, 110–111
central nervous system and, 98–99
cryogens in, 93, 109–114
cytokines and, 103–109
definition, 94
disease and, 96–97
induction of, failure, in vertebrates, 95–96
interferon-α and, 107–108
interferon-γ and, 107
interleukin 1 and, 103–106
interleukin 6 and, 108
α-melanocyte-stimulating hormone and, 111–112
methodological problems in research
endotoxin contamination, 99–102
latency to onset of fever in distinguishing lipopolysaccharide fever from endogenous pyrogen fever, 101–102
polymyxin B use, 100
shape of fever curve in distinguishing lipopolysaccharide fever from endogenous pyrogen fever, 100–101
nature of, early thoughts on, 94–95
nonpathological conditions and, 97–98
circadian rhythm in body temperature, 116

exercise hyperthermia, 114–115
postovulatory rise in body temperature, 115–116
stress hyperthermia, 117
prostaglandins and, 98–99
putative endogenous antipyretics in urine, 112–114
putative mediators
attenuators, 109–114. *See also* Fever, cryogens in
inducers, 102–109. *See also* Fever, pyrogens in
pyrogens in, 93, 102–109
nonpathological conditions and, 114–117
response of vertebrates and invertebrates, 95
tumor necrosis factor and, 106–107, 114
Fibroblast growth factor
acidic, glycosaminoglycan interactions, 495–496
action, glycosaminoglycans and, 496–498
basic, glycosaminoglycan interactions, 495
Fibronectic, glycosaminoglycan interactions, 501–502
Filamin, cleavage in platelet aggregation, calpain system and, 829
Fluid-electrolyte balance
cellular recognition of changes in extracellular concentrations of ions, 400–403
calcium, 389–390, 393–400. *See also* Calcium sensing
cells that respond to several extracellular ions, 402
chloride, 401
hydrogen and sodium, 401–402
magnesium, 401
phosphate, 401
potassium, 400–401
potential importance of ion sensing at cellular interfaces, 402–403
recognition of multiple ions by single cell type, 402–403
effects of cellular activation by calcium-mobilizing hormones on transmembrane ionic fluxes, 403–404
extracellular ions as first messengers and their relationship to intracellular ions and cellular activation, 403–404
ions and other factors that act as both first and second messengers, 403
Fluid phase endocytosis, cellular uptake of retinol, 971–972
Frank-Starling relation, isolated cardiac myocyte shortening related to, 421–424

G

Ganglion cells, retinal, 463–471
Gastric motility, oxytocin and, 338–339
Gastric secretion, oxytocin and, 338–339
Gender, cardiovascular response to stress and, 324
Gene expression
in animal models that closely mimic human physical activity, inferred sites for, 566
glycosaminoglycans and, 518–520
Gene gating hypothesis, nuclear pore complexes and, 935–936
Genetic factors, dopaminergic transmission reactivity, 205
Glucose, sodium-linked absorption in fetal lung, 1006–1007
Glucose uptake, skeletal muscle, single bout of exercise and, 545–547
Glycerophosphorylcholine, 1094–1097
accumulation in renal cells, osmotic induction of, 1095–1096
renal metabolism, 1094–1095
transport, 1096–1097
Glycerophosphorylcholine:choline phosphodiesterase, in renal glycerophosphorylcholine metabolism, 1095
Glycogen, depletion, muscle fatigue during exercise and, 542–543
Glycogenolysis, cerebral, histamine and, 17
Glycogen synthase, covalent modification, 301–302
Glycosaminoglycan(s)
atherosclerosis and, 493–494
interaction with transcription factors, 506–507, 521–522
molecular properties, 482–486
nerve cell development and regeneration and, 512–515
interaction with cell adhesion proteins, 513–514
interaction with extracellular matrix, 515
regulation of cellular neurotropic factors, 512–513
protein interactions, 486–507. *See also* Glycosaminoglycan-binding proteins
regulation of cellular processes, 507–518
nerve cell development and regeneration and, 512–515
smooth muscle cell proliferation, 507–512
tumor growth, angiogenesis, and metastasis, 515–518
regulation of gene expression, 518–520
effects on liver protein expression, 518–519
effects on mammary protein expression, 519–520
smooth muscle cell proliferation and, 507–512
regulation of cellular events, 507–509
regulation of protein expression, 509–511
regulation of smooth muscle cell growth, 511–512
tumor growth, angiogenesis, and metastasis and, 515–518
Glycosaminoglycan-binding proteins, 486–507
extracellular matrix proteins, 500–504
fibronectin, 501–502
laminin, 503–504
thrombospondin, 504
vitronectin, 502–503
growth factors, 494–498
fibroblast growth factor
acidic, 495–496
basic, 495
glycosaminoglycans and action of, 496–498
lipolytic enzymes, 498–500
plasma lipoproteins, 490–494
apolipoprotein B-100, 490–492
apolipoprotein E, 492–493
platelet factor 4, 504–505
protease inhibitors, 486–490
antithrombin III, 486–489
heparin cofactor II, 489
model for heparin-antithrombin interaction, 489–490
structure and properties, 486–507
transcription factors, 506–507
viral coat proteins, 505–506
Gonadotropin(s)
release, oxytocin and, 335
secretion, histaminergic neurons and, 25
Gonadotropin-releasing hormone, release, oxytocin and, 335
Grooming behavior, oxytocin and, 344–345
Growth and development, at high altitude, 1155
animal studies, 1156–1157
Growth factors, glycosaminoglycan interactions, 494–498
Growth hormone
general effects, 1035
localization and coexistence, 1035
neurotrophic effects, 1035–1036
secretion, histaminergic neurons and, 24
Guanosine 3′,5′-cyclic monophosphate (cGMP), accumulation in brain, histamine and, 17

H

Habenula region, dopaminergic transmission, 169–170
Habituation, dopaminergic transmission and, 195
Hallucinations, H_2 antagonists and, 30
Heart
afferent innervation, 618–619
catecholamine regulation of calcium transport, 752–753

charge movement currents in myocytes, 885
early embryonic
developmental stages, 60
effect of sympathetic and paasympathetic chemical transmitters, 82
electrical activity and related functions
optical approaches to ontogeny of, 53–83
optical methods for monitoring, 55–59. *See also* Electrical activity, in early embryonic heart; Optical system
excitation-contraction coupling and heartbeat, 77–81
characteristics of initial coupling, 79–81
implications, 81
optical detection of first contraction, 77
spatial distribution of contractility, 78–79
innervation, development of, 82
ontogenesis, 59–60
ontogenesis of neural control of function, 81–82
optical detection of first contraction, 77
pacemaker and action potential propagation, 70–77
assessment of pacemaking area, 74–76
conduction patterns of excitation, 72–73
double pacemaker, 72
localization of pacemaker site, 70–72
regional gradient of pacemaker potential with reference to organization of pacemaking area, 76–77
switching phenomenon of pacemaker, 72
primary morphogenesis, 60
rhythmicity
generation of, 66–67
pacemaker potential, 69–70
regional differences in, 67–69
spatial distribution of contractility, 78–79
energy requirement of calcium transport, 745–747
during isometric contraction, 746–747
at rest, 745–746
energy requirement of sodium-potassium transport, 736–737
reflexes from. *See* Cardiac reflexes
rhythmicity
generation of, 66–67
arrhythmic action potentials, 67
calcium dependence, 67
temperature dependence, 66–67
regional differences, 67–69
congenital double heart, 67–68
cultured multiple heart, 68–69
embryonic cultured double heart, 68
optical action signals from surgical divisions, 67
thyroid hormone regulation of calcium transport, 756–757
thyroid hormone regulation of sodium-potassium transport, 750–751
ventricular receptor stimulation and, 639
Heart failure, cardiac reflexes in, 647
Heart rate, atrial receptor stimulation and, 627–629
Heart size, exercise training and, 569–570
Hebb's postulate, synaptic visual plasticity, 596–598
Heme synthesis, skeletal muscle adaptation to aerobic training and, 551
Hemoglobin, oxygen affinity, high altitude and, 1145–1148
Heparan sulfate. *See* Glycosaminoglycan(s)
Heparin cofactor II, 489
Hippocampus, dopaminergic transmission, 169
Histamine
biosynthesis, 2–4
regulation, 4
inactivation, 6–7
metabolism, 2–8
release, 5–6
control by autoreceptors and heteroreceptors, 5–6
in vitro, 5
in vivo, 5
storage, 4–5
mast cells, 4, 13–14
nonneuronal, 13–14
transmethylation, 6–7
turnover, 7–8
drug-induced changes, 8
isotopic studies, 7
nonisotopic studies, 7–8
Histamine antagonists
H_1 antagonists, discriminative properties, 30
H_2 antagonists, hallucinatory properties, 30
Histamine receptors
in brain, 14–22
H_1 receptors
in brain, 14–18
cAMP accumulation and, 16–17
cGMP accumulation and other biochemical responses, 17
distribution in brain, 15–16
electrophysiological responses, 17–18
glycogenolysis, 17
inositol phospholipid hydrolysis, 16
molecular properties, 14–15
H_2 receptors
adenylate cyclase activation, 18–19
in brain, 18–20
electrophysiological responses, 20
localization in brain, 19–20
molecular properties, 18
phospholipid methylation and other biochemical responses, 19
H_3 receptors
actions mediated by, 22
in brain, 20–22
distribution in brain, 21–22
molecular properties, 20–21
Histaminergic neurons
afferents to, 13
disposition of neuronal pathways, 8–13
lesion studies, 8–9
immunohistochemical localization, 9
localization of histaminergic perikarya, 9–10
morphology, 10–11
ontogeny, 12–13
other putative neurotransmitters in, 11
pathways and projection fields, 11–12
role in cardiovascular regulation, 25–26
role in control of cerebral circulation, 26
role in control of nociceptive responses, 27
role in control of various behaviors, 29–30
aggressive behaviors, 29
discriminative properties of H_1 antagonists, 30
drinking and eating, 29
hallucinatory properties of H_2 antagonists, 30
learning, 30
motor activity, 29
self-stimulation, reinforcement, and aversion, 29–30
stress, 29
role in control of vigilance, sleep, and wakefulness, 27–29
role in emesis and motion sickness, 27
role in neuroendocrine control, 22–25
adrenocorticotropic hormone secretion, 24–25

gonadotropin secretion, 25
growth homrone secretion, 24
posterior pituitary hormone secretion, 22–23
prolactin secretion, 23
thyrotropin secretion, 24
role in thermoregulation, 26–27
in tuberomammillary nucleus, 9–10
Histidine, transport, 2
L-Histidine decarboxylase
inhibition, 3–4
localization, 3
properties, 2–3
History, family history, cardiovascular response to stress and, 326
Horizontal cells, retinal, 451–454
Hormones
calcium homeostasis and, 372–374
cation transport and, 749–757
calcium transport, 752–757
sodium-potassium transport, 749–752
neuropeptide. *See* Neuropeptide(s)
regulation of plasma membrane calcium pump, 146
Hyaluronic acid. *See* Glycosaminoglycan(s)
Hydrocortisone, epinephrine-induced fetal lung liquid reabsorption and, 1003–1004
Hydrogen, extracellular, cellular recognition of changes in, 401–402
6-Hydroxydopamine, lesions of mesocorticolimbic dopaminergic cell bodies, 158–159
***N*-(4-Hydroxyphenyl)retinamide,** plasma retinol homeostasis and, 978–980
5-Hydroxytryptamine, interaction with thyrotropin-releasing hormone, 1033
Hyperosmotic solutions, intrapelvic perfusion, renorenal reflexes and, 674
Hypertension
calpain-mediated proteolysis in erythrocytes in, 831–832
renal nerves and, 676–677
renorenal reflexes and, 677
Hyperthermia
exercise-induced, 114–115
malignant, cation transport and, 759–761
stress-induced, 117
Hypertonicity
magnitude of, organic osmolyte accumulation in renal medullary cells and, 1104
protection against, compatible organic osmolytes and, 1105–1107
renal medullary cell adaptation to, model of, 1093–1094
Hypothalamoadenohypophysial system, oxytocin and, 333–336, 354–355
Hypothalamus
afferent renal nerve fiber projections, 667
electrophysiological effects of oxytocin, 353
Hypoxia
aerobic training and, 552
calcium homeostasis during, 761–762
Hypoxic environment
developmental adaptation, 1155–1157
experimental studies in animals, 1156–1157
human growth at high altitude, 1155
respiratory function in humans, 1155–1156
embryonic adaptation: birds, 1152–1155
chorioallantoic membrane, 1153–1154
diffusion of gases through eggshell, 1152–1153
effects of hypoxia on avian embryos, 1152
experimental research, 1154
phenotypic and genotypic adaptations, 1153
embryonic adaptation: mammals, 1150–1152
maternal physiology and, 1151–1152
placental oxygen transport, 1150–1151
placental weight and morphology and, 1151
loss of adaptation to, 1157–1158
physiological adaptation to
definition of terms, 1136
oxygen transport in mammals and birds, 1135–1160. *See also* Oxygen transport
preadaptation and natural selection in, 1136–1137

I

Immunity, in respiratory tract. *See* Respiratory immunity
Immunoglobulins, secretory, in respiratory secretions, 1119–1120
Inositol, 1100–1103
accumulation in renal cells, osmotic regulation of, 1101–1103
metabolism and transport, 1100–1101
osmotic regulation of transport in renal cells, 1101–1103
Inositol phospholipids, hydrolysis, H_1-receptor-mediated, 16
Inositol trisphosphate, in excitation-contraction coupling, 894–896
activation of release channel, 894–895
disposal of transmitter, 895–896
release of transmitter, 894
synthesis of precursor, 894
Insulin, neurotrophic actions, 1036
Interferon-α, fever and, 107–108
Interferon-γ, fever and, 107
Interleukin 1
fever and, 103–106
in dialysis patient, 113
urinary inhibitor proteins, 113–114
Interleukin 6, fever and, 108
Intestine
energy requirement of sodium-potassium transport, 741
esterification of retinol, 956–958
acyl-coenzyme A:retinol acyltransferase in, 957
fatty acids of lymph retinyl esters in, 956–957
lecithin:retinol acyltransferase in, 957–958
thyroid hormone regulation of sodium-potassium transport, 752
vitamin A absorption, 954–961. *See also* Vitamin A metabolism
Ion channels
homologous properties, 1075–1076
in leukocytes, 775–804
in macrophages, 776–785
molecular kinetics
constraints of reality imposed on ideal kinetics, 1071–1074
kinetic homologies, 1075–1076
variability in kinetics between channels with different structures, 1072
variability in kinetics intrinsic to single channels, 1072–1073
variability in permeation properties of open channels, 1073–1074
physiological role of ionic conductances
in macrophages, 783–785
in neutrophils, 786–787
in T cells, 796–799
structural homologies between sodium, calcium, and potassium channels, 1075
terminology, 775–776
Ischemia
calcium homeostasis during, 761–762
cation transport and, 761–762

K

Keratan sulfate. *See* Glycosaminoglycan(s)
Kidney
blood flow, stress and, 313–316
cells, calcium sensing, 396–398

collecting duct
chloride transport, 271–273
sites of acid-base transports, 272
sites of transepithelial chloride fluxes, 272–273
sites of transepithelial sodium and potassium fluxes, 271–272
energy requirement of sodium-potassium transport, 740
innervation. *See also* Renal nerves
intrinsic, 660–661
medulla. *See* Renal medullary cells
renorenal reflexes, 672–676. *See also* Renorenal reflexes
thyroid hormone regulation of sodium-potassium transport, 751–752
Kidney disease, plasma retinol homeostasis and, 980
Kidney function, atrial receptor stimulation and, 630–634

L

Lactate dehydrogenase, skeletal muscle adaptation to exercise training, 555–556
Laminin, glycosaminoglycan interactions, 503–504
Learning, histaminergic neurons in, 30
Learning processes, dopaminergic transmission and, 160
Lecithin:retinol acyltransferase, in intestinal esterification of retinol, 957–958
Leukocyte(s)
ion channels in, 775–804
lymphocytes. *See* Lymphocyte(s)
phagocytic. *See also* Macrophage(s); Neutrophil(s),
ion channels in, 776–787
Lipid(s), activation of plasma membrane calcium pump, 133
Lipoprotein(s), plasma, glycosaminoglycan interactions, 490–494
Liver
catecholamine regulation of calcium transport, 753
cell types, 961–962
energy requirement of calcium transport, 748
energy requirement of sodium-potassium transport, 738–740
protein expression, glycosaminoglycans and, 518–519
thyroid hormone regulation of sodium-potassium transport, 751
vitamin A in, 961
Locomotor activity
hyperactivity, dopaminergic neuron activation and, 172–176
mesocorticolimbic dopaminergic neuron lesions and, 159
Long-term potentiation, calpain system in, 833–835
Lung(s)
oxygen transfer, at high altitudes, 1139–1140
oxygen transport, at high altitudes, 1137–1142
postnatal transition to adult lungs, lung liquid and, 1009–1010
Lung liquid, fetal, 991–1011
acidification of, 1001
composition of, 997–998
epithelial permeability, ion flux, and secretion rate, 992–995
calculation of epithelial permeabilities and ion fluxes, 994
measurement in intact fetal sheep, 992–993
measurement of lung liquid secretion and volume, 994–995
measurements in postnatal lungs, 995
nonelectrolyte permeabilities, 993–994
equations for compartmental analysis, 1011
fate of, 996
historical perspective, 992
lung development and, 996–997
postnatal transition to adult lungs, 1009–1010
postnatal balance between secretion and reabsorption, 1010
postnatal changes in ion transport, 1009–1010
sodium transport across alveolar epithelia of adult lungs, 1009
reabsorption of, 1001–1008
adenosine 3′,5′-cyclic monophosphate and, 1003
β-adrenergic agonists and, 1002–1003
effect of labor, 1003
epidermal growth factor and, 1007
epinephrine and, 1002–1006. *See also* Epinephrine
prolactin and, 1007
sodium-glucose cotransport, 1006–1007
vasopressin and, 1007
ventilation, paracellular permeability, and postnatal reabsorption, 1007–1008
secretion of, 995–1001
chemical potential, 999–1000
electrical potential difference, 999
estimates of transport potential, 1000–1001
measurement, 994–995
measurement of flux ratios, 999
mechanism of, 998–1001
patterns of ion permeabilities, 1001
rate of, 996
solvent drag, 1000
volume, 995–996
volume, 995–996
Luteinizing hormone-releasing hormone, acetylcholine and, in frog sympathetic ganglia, 701–702
Lymphocyte(s). *See also* B cell; T cell
ion channels in, 787–804
Lymphoid tissue, in respiratory tract, 1120–1122
bronchus-associated lymphoid tissue, 1121–1122
lymphoid aggregates, 1122
Lysophospholipases, in renal glycerophosphorylcholine metabolism, 1094–1095

M

Macrophage(s)
chloride conductances, 781–782
ion channels in, 776–785
ionic conductances induced by specific ligands or cell functions, 782–783
adenosine triphosphate, 782
phagocytosis, 782–783
nonselective cation conductance(s), 782
physiological role of ionic conductances, 783–785
potassium conductances in, 776–781
calcium-activated inwardly rectifying, 779–780
inactivating outward potassium channel, 780
large calcium- and voltage-activated, 778–779
poorly inactivating outward potassium channel, 780–781
voltage-dependent inwardly rectifying, 776–778
Magnesium, extracellular, cellular recognition of changes in, 401
Malonyl-coenzyme A, skeletal muscle, single bout of exercise and, 547
Mammary cell, protein expression, glycosaminoglycans and, 519–520
Mast cells
in brain, 13–14
histamine storage, 4, 13–14
Maternal behavior, oxytocin and, 343–344
Mathematical models, chloride transport by high-resistance heterocellular epithelia, 252–263. *See also* Chloride transport
α-Melanocyte-stimulating hormone, fever and, 111–112
Melanocyte-stimulating hormone (MSH)
localization, processing, and extra-adrenal effects, 1023–1024
neurotrophic qualities. *See* Neurotrophic factors, ACTH/MSH peptides
Membrane fusion, calpain-mediated proteolysis in erythrocytes and, 832

Membrane potential, ionic conductances and, 783–784
in lymphocytes, 796–797
Memory, oxytocin and, 345–346
Mental stress, cardiovascular and neuroendocrine responses to, 307–309
Metabolic rate, basal, cation transport and thermogenesis and, 757–759. *See also* Cation transport
Metabolism
cardiac myocyte, exercise training and, 574
cellular, apical sodium entry in epithelia and, 437–438
Metal ions, skeletal muscle excitation-contraction coupling and, 875
Metastatic disease, glycosaminoglycans and, 515–518
***N*-Methyl-D-aspartate receptor hypothesis,** synaptic visual plasticity, 598–601
***tele*-Methylhistamine,** oxidative deamination, 7
Mineral(s), regulation, oxytocin and, 339
Mitochondria, skeletal muscle adaptations to aerobic exercise training, 547–553
control of protein expression, 548–551
description of adaptation, 547–548
factors regulating molecular changes, 551–553
fatigue and, 553
heme expression, 551
localization of signal for adaptation, 548
messenger RNA, 548
protein synthesis, 548
Mitochondria-rich cells
amphibian skin, electrolyte transport, 239
epidermal, 236
cell density and skin conductance, 245–246
cell volume studies, 247–248
chloride conductive pathways, 248
chloride transport, 237, 239, 245–251
amiloride and, 258–259
anion specificity and concentration dependence of anion fluxes, 250
cAMP dependence of chloride conductance, 250–251
electron microprobe studies, 249–250
ouabain and, 256–257
current density profiles above epithelium, 246–247
ionic pathways, 245–251
sodium conductive pathways, 247
water permeability and volume response to osmotic perturbations, 248
γ-type, 265
proton transport, 264–265
specialized for other functions, 266
subpopulations with specialized functions, 275
urinary bladder, chloride transport, 269–270
Mitogens, T cell response to
calcium channels and, 797–798
potassium channels and, 797
Models
heparin-antithrombin interaction, 489–490
ion channel kinetics, 1051
activation, 1053
Hodgkin-Huxley activation model, 1055–1057
inactivation process, 1065–1069
subunit model for activation, 1057–1062
mathematical. *See* Mathematical models
molecular and cellular adaptations to exercise, 544–545
heavy-resistance training, 560–561
neurotransmission, 691–694
renal medullary cell adaptation to hypertonicity, 1093–1094
retinol recycling, 975–976
skeletal muscle hypertrophy
compensatory overload-induced, 563–564
stretch-induced, 562–563
Motion sickness, histaminergic neurons in, 27
Motivation, dopaminergic transmission and, 160
Motor activity
control, histaminergic neurons in, 29
development of motor behavior, ACTH/MSH peptides in, 1028–1029
oxytocin and, 341
MSH. *See* Melanocyte-stimulating hormone
Muscle. *See also* Cardiac myocytes; Skeletal muscle
blood flow, exercise training and, 573–574
cotransmission at, functional meaning, 707
invertebrate, cotransmitters at, 703–707
smooth. *See* Smooth muscle
striated
adenosine triphosphate as cotransmitter in, 687
cotransmission in, 700–701
Myocardial infarction, cardiac reflexes in, 645–647
Myocardial ischemia, cardiac reflexes in, 645–647
Myofibrillar protein, cardiac, exercise training and, 570–571
Myoglobin, skeletal muscle adaptation to aerobic training, 559
Myosin isoforms
in compensatory overload-induced hypertrophy, 564
switching
chronic stimulation and, 556–558
decreased weight bearing and, 558
factors regulating, 558–559
fatigue during exercise and, 559
human physical activity and, 556

N

Natriuresis, atrial receptors in, 632
Natural killer (NK) cells
ion channels in, 788–799
potassium conductances in, 783–794
Nerve cell, development and regeneration
ACTH/MSH peptides in, 1025–1032
glycosaminoglycans and, 512–515
neuropeptide hormones and, 1019–1022. *See also* Neurotrophic factors
target cells in, 1022–1023
Nervous system
autonomic, cardiovascular regulation and, ontogenetic development, 82
central
cotransmission. *See* Cotransmission
fever and, 98–99
oxytocin in, 348–350. *See also* Oxytocin
development, neuropeptide hormones in. *See* Neurotrophic factors
sympathetic
afferent activity, 624–625
stress and, 316–317
Neuroendocrine system, control, histaminergic neurons in, 22–25
Neuromuscular junction, vertebrate, cotransmission at, 701
Neuron(s)
dopaminergic. *See* Dopaminergic network
histaminergic. *See* Histaminergic neurons
proteolytic modification of submembrane skeleton, calpain system in, 833–835
Neuropeptide(s)
neuroendocrine regulation, stress and, 321–322
neurotrophic effects, 1017–1038. *See also* Neurotrophic factors

Neuropeptide Y
coexistence with other bioactive substances in neurons, 691
in cotransmission at vas deferens, 697–698
Neurotransmitters
coexistence of adenosine triphosphate with, in adrenal gland and neuronal vesicles, 687
cotransmission. *See* Cotransmission
Neurotrophic factors, 1017–1038
ACTH/MSH peptides, 1025–1032
in central nervous system development, 1027–1028
control of neuronal sprouting, 1027
in development of motor behavior, 1028–1029
electrophysiological studies, 1025–1027
endplate morphology, 1027
in neuronal regeneration, 1029–1032
in peripheral nervous system neuronal development, 1025–1027
characteristics of, 1018–1019
clinical implications, 1037
corticotropin-releasing factor, 1032
growth hormone, 1035–1036
initiation of growth and homeostatic maintenance, 1018
insulin, 1036
nerve development and, 1019–1021
ACTH/MSH peptides in, 1025–1028
neurite fasciculations, 1019
patterns of growth: axonal pathfinding, 1019
synapse formation, 1020–1021
synaptic rearrangement, 1021
nerve regeneration and, 1021–1022
ACTH/MSH peptides in, 1029–1033
direction of axonal regrowth, 1021
patterns of innervation, 1021
synapse formation, 1021
synaptic rearrangement, 1021–1022
neuronal homeostasis and, 1036–1037
selectivity of innervation, 1018–1019
significance of, 1036–1037
somatostatin, 1036
specificity versus nonspecificity, 1018
substance P, 1034–1035
target cells in neuronal development and regeneration, 1023
thyrotropin-releasing hormone and thyrotropin, 1032–1034
localization and coexistence, 1032–1033
mechanism of action, 1033–1034
neurotrophic effects, 1033
Neutral protease, calcium-activated. *See* Calpain system
Neutrophil(s)
activation, calpain and protein kinase C activity in, 835–836
calcium-activated cation conductance in, 786
chloride conductances in, 786
ion channels in, 785–787
physiological role of ionic conductances, 786–787
potassium conductances in, 785–786
Nociception, control, histaminergic neurons in, 27
Norepinephrine
in cotransmission at vas deferens, 697–698
kinetics, stress and, 318
in synaptic plasticity, 604–605
Nuclear envelopes
permeability of, 921–922
properties of, 910
protein transport across, 929–931
anchors, 929–931
shuttles, 929
Nuclear lamina, 912. *See also* Nuclear pore complex
biochemical components, 915–916
fate of, during mitosis, 919–920
Nuclear matrix, 912
biochemical components, 916
Nuclear pore complex, 909–936
associated cellular structures, 912–913
biochemical components, 915–917
chromatin, 912–913
cytoskeletal elements, 913
lamina and nuclear matrix, 912
nuclear matrix concept, 916
biochemical components, 913–915
integral membrane proteins, 913
p-62 and *O*-linked *N*-acetylglucosamine nucleoporins, 914–915
peripheral proteins, 914–915
export of RNA from nucleus, 931–934
anchorage of RNA to nuclear matrix, 931
nuclear substructures in, 934
nucleosidetriphosphatase involved in RNA export, 931
RNA structural features required for RNA export, 931–934
fate of, during mitosis, 920
function of nuclear pore in nucleus-cytoplasm exchanges, 920–929
interactions of polypeptide hormones and their receptors with target cell nuclei, 927–929
morphological observations, 920–921
nuclear localization of steroid hormone receptors, 926–927
O-linked *N*-acetylglucosamine nucleoporins in protein import, 925–926
permeability of nuclear envelope, 921–922
receptors for nuclear localization sequence, 925
signal-mediated nuclear protein transport, 922–925
gene gating hypothesis and, 935
morphology, 910–913
associated cellular structures, 912–913
nuclear pore complex number and density, 910
properties of nuclear envelope, 910
ultrastructure, 910–912
nuclear pore-nuclear lamina assembly and disassembly during cell cycle, 917–920
fates of nuclear pore complex and lamina components during mitosis, 919–920
in vitro nuclear assembly and disassembly, 917–918
regulated entry into mitosis and nuclear pore-lamina disassembly, 918–919
regulating transport across nuclear envelopes, 929–931
anchors in, 929–931
shuttles in, 929
signal transduction into nucleus, 929–931
ultrastructure, 910–912
Nucleus accumbens, dopaminergic transmission, 161–162

O

Olfactory system, oxytocin and, 344
Opiates, interaction with thyrotropin-releasing hormone, 1033
Optical system, monitoring electrical activity in early embryonic heart, 55–59. *See also* Electrical activity
applications to cardiac muscle, 58–59
functional differentiation of conduction system, 81
future perspectives, 81–82
recording system, 57–58
voltage-sensitive dyes, 55–57
mechanisms, 56
wavelength dependence, 56
Osmolytes, organic, in renal medulla, 1081–1109. *See also* Renal medullary cells
Osteoclasts, calcium sensing, 398
Ouabain, chloride transport and, 256–257
Oxidative phosphorylation, cardiac myocyte, exercise training

and, 574
Oxygen flux
maximal, aerobic training and, 543–542
skeletal muscle adaptation to aerobic training and, 559–560
Oxygen-hemoglobin affinity, high altitude and, 1145–1148
Oxygen paradox, 761
Oxygen transport, at high altitudes, 1137–1150
arterial-venous oxygen difference, 1145
blood flow and, 1144–1145
blood oxygen transport, 1142–1148
embryonic adaptation in birds, 1152–1155
embryonic adaptation in mammals, 1150–1152
erythropoiesis and erythropoietin and, 1143–1144
hemoglobin affinity for oxygen and, 1145–1148
oxygen diffusion from blood to tissues, 1148–1149
placental oxygen transport, 1150–1151
polycythemia and, 1142–1143
pulmonary, 1137–1142
pulmonary circulation, 1140–1142
pulmonary oxygen transfer, 1139–1140
tissue capillarity and, 1149–1150
tissue oxygen transport, 1148–1150
ventilatory function and, 1137–1139
Oxytocin
action via other neurotransmitters, 350–351
behavioral effects, 341–347
brain oxytocin-binding sites relative to, 355
drug dependence and tolerance, 346–347
feeding, 345
female sexual behavior, 342–343
grooming and stereotyped behaviors, 344–345
learned behaviors, 345–347
male sexual behavior, 342
maternal behavior, 343–344
memory processes, 345–346
reinforced conditioning, 346
spontaneous behaviors, 341–345
brain-binding sites in relation to physiological and behavioral effects, 353–355
cardiovascular regulation and, 337–338
central effects, 331–356
centrally mediated autonomic effects, 336–340
brain oxytocin-binding sites relative to, 355
cardiovascular regulation, 337–338
cerebral vasculature, 338
gastric motility and secretion, 338–339
hydromineral regulation, 339
thermoregulation, 339–340
centrally mediated somatic effects, 340–341
analgesia, 340
brain oxytocin-binding sites relative to, 355
motor activity, 341
sleep-wake rhythms, 340–341
in central nervous system, 348–350
central physiological effects, 332–341
analgesia, 340
brain oxytocin-binding sites relative to, 354–355
cardiovascular regulation, 337–338
centrally mediated autonomic effects, 336–340
centrally mediated somatic effects, 340–341
cerebral vasculature, 338
gastric motility and secretion, 338–339
hydromineral regulation, 339
motor activity, 341
neuroendocrine regulatory processes, 332–336
sleep-wake rhythms, 340–341
thermoregulation, 339–340
cerebral vasculature and, 338
cerebrospinal fluid, passage into brain, 348
cotransmitter function, 708
electrophysiological effects at cellular levels, 351–353
brain stem, 352
hypothalamus and forebrain, 353
limbic areas, 352
spinal cord, 351–352
sympathetic preganglionic and ganglionic neurons, 351
gastric motility and secretion and, 338–339
hydromineral regulation and, 339–340
hypothalamoadenohypophysial system and, 333–336
ACTH and corticotropin-releasing hormone release, 335–336
brain oxytocin-binding sites relative to, 354–355
gonadotropin and gonadotropin-releasing hormone release, 335
prolactin release, 333–335
neuroendocrine regulatory processes, 332–336
brain oxytocin-binding sites relative to, 354–355
hypothalamoadenohypophysial system, 333–336
oxytocin and oxytocin release, 332–333
neuronal plasticity and, 353
origin of centrally acting oxytocin, 347–350
passage from blood to cerebrospinal fluid/brain areas, 347
in posterior pituitary, 709
release, 332–333
brain oxytocin-binding sites relative to, 354
target areas in brain for, 347–350
thermoregulation and, 339–340

P

Pain, perception. *See* Nociception
Parathyroid glands
calcium homeostasis and, 374
calcium sensing, polyfunctional regulator of second messengers and other intracellular regulatory mechanisms, 389–390
Parathyroid hormone secretion
calcium-regulated
acute regulation, 374–377
cAMP and, 390
changes in extracellular calcium persisting for days to weeks or longer, 380–382
changes in extracellular calcium persisting for hours to several days, 378–380
coupling of calcium-mediated changes in intracellular mediators to, 390
cytosolic calcium and, 390–392
does calcium receptor show positive cooperativity, 388
effects of agents interacting with cell surface on regulation of parathyroid function by divalent cations, 388–389
effects of polyvalent cations on dopamine-stimulated cAMP accumulation in bovine parathyroid cells and, 386–388
effects of polyvalent cations on inositol phosphate accumulation in bovine parathyroid cells and, 385–386
evidence for receptor-mediated regulation, 385–389
mechanisms underlying inverse control by extracelular calcium, 382–393
mediators that stimulate parathyroid hormone release at low or resting cytosolic calcium concentrations, 383–385
phosphoinositide metabolism and protein kinase C and, 392–393
physiology, 374–382
polyvalent cation-regulated changes in intracellular calcium and, 385
relationship between calcium and parathyroid hormone release in intact parathyroid cells, 382
sustained changes in extracellular calcium persisting for minutes to several hours, 377–378

use of permeabilized parathyroid cells in study of, 382–383
cAMP and control of parathyroid hormone release by nonionic secretagogues, 390
Peptides, in cotransmission, 688–689, 689–690
pH
apical sodium entry in epithelia and, 437–438
low, muscle fatigue during exercise and, 542
potassium conductance in T cells and, 790–791
Phagocytosis, induction of conductance in macrophages, 782–783
Phosphate
extracellular, cellular recognition of changes in, 401
high-energy, aerobic training and, 552
Phosphoinositide metabolism, calcium-regulated parathyroid hormone secretion and, 392–393
Phospholipase A, in renal glycerophosphorylcholine metabolism, 1094
Phosphorylase, phosphorylation, covalent modification. *See* Covalent modification
Phosphorylase kinase, phosphorylation, covalent modification, 298–301
Phosphorylation
kinase-mediated, activation of plasma membrane calcium pump, 134
phosphorylase, covalent modification. *See* Covalent modification
phosphorylase kinase, covalent modification, 298–301
Photoreceptors. *See* Retina
Pituitary-adrenal axis, response to stress, 319–321
Pituitary gland, posterior, vasopressin and oxytocin in, 709
Pituitary hormones
anterior
release, oxytocin and, 333–336, 354–355
secretion, histaminergic neurons and, 23–24
posterior, secretion, histaminergic neurons and, 22–23
Place conditioning
dopaminergic network in, 203–204
evaluation of dopaminergic transmission in reinforcement processes, 202–204
advantages and limits, 202–203
Placenta, in physiological adaptation to high altitude
oxygen transport, 1150–1151
weight and morphology and, 1151
Placental cells, calcium sensing, 398–399
Plasma membrane
calcium pump, 129–146. *See also* Calcium pump
saturable binding of iodinated retinol-binding protein to, 973
Platelet(s), activation, calpain and protein kinase C activity in, 836
Platelet aggregation, cleavage of talin and filamin, calpain system in, 829–831
Platelet factor 4, glycosaminoglycan interactions, 504–505
Polycythemia, of high altitude, 1142–1143
Potassium, extracellular, cellular recognition of changes in, 400–401
Potassium channels
in B cells, 799–800
kinetic homologies to other ion channels, 1075–1076
in macrophages, 776–781. *See also* Macrophage(s)
in natural killer cells, 788–794
in neutrophils, 785–786
structural homologies to other ion channels, 1075
in T cells, 788–794
response to mitogens and, 797
Potassium transport. *See also* Cation transport
renal collecting duct, 271–272
p62 protein, nuclear pore complex, 914
Principal cells
amphibian skin, electrolyte transport, 237–238
epidermal
apical membrane, chloride permeability, 242–244
basolateral membrane
chloride-chloride and chloride-bicarbonate exchange, 245
chloride conductance, 245
chloride transport
amiloride and, 258
ouabain and, 256
a functional syncytium, 237–238
intracellular chloride concentration, 241–242
sodium-potassium-2 chloride cotransport, 244–245
epithelial, functional organization, 273–275
renal collecting duct, chloride transport, 272–273
urinary bladder
apical membrane conductances, 267
basolateral membrane conductances, 267–268
chloride transport, 267–269
intracellular ion concentration, 268
syncytial-like organization, 268–269
Prolactin
fetal lung liquid secretion and, 1007
release, oxytocin and, 333–335
secretion, histaminergic neurons and, 23–24
Prostaglandins, fever and, 98–99
Protease(s), calcium-dependent. *See* Calpain system
Protease inhibitors
antithrombin III, 486–489
heparin-antithrombin interaction, model for, 489–490
heparin cofactor II, 489
structure and properties, 486–490
Protein(s)
activation of plasma membrane calcium pump, 134
degradation
in compensatory overload-induced hypertrophy, 563
in stretch-induced hypertrophy, 563
expression
adaptive changes in stretch-induced hypertrophy, 562–563
skeletal muscle adaptation to aerobic training, 548
extracellular matrix, glycosaminoglycan interactions, 500–504
glycosaminoglycan-binding. *See* Glycosaminoglycan-binding proteins
hepatic, glycosaminoglycans and, 518–519
mammary, glycosaminoglycans and, 519–520
nuclear pore complex
integral membrane proteins, 913
peripheral proteins, 914–915
nuclear transport, signal-mediated, 922–925
synthesis
in compensatory overload-induced hypertrophy, 563
mitochondrial, skeletal muscle adaptation to aerobic training, 548
in stretch-induced hypertrophy, 563
viral coat, glycosaminoglycan interactions, 505–506
Protein kinase C
calcium-regulated parathyroid hormone secretion and, 392–393
proteolysis, calpain system and, 835–836
Protein phosphorylation, covalent regulation, 285–303
covalent modification complexity. *See also* Covalent modification
classification, 289–302
physiological rationale, 287–289
reversibility as criterion of suitable covalent control mechanism, 286–287
Proteoglycans. *See also* Glycosaminoglycan(s)
intracellular granule proteoglycans, 483
membrane-associated proteoglycans, 484–486
properties, 482–486
secreted proteoglycans, 483–484

Proteolysis
activation of plasma membrane calcium pump, 133–134
calcium-dependent. *See* Calpain system
Proton transport, in high-resistance heterocellular epithelia, 264–265
Pulmonary arterial pressure, physiological adaptation to high altitudes, 1140–1142
Pyrogens, fever and, 93, 102–109

R

Race, cardiovascular response to stress and, 324–325
Radionuclide studies, histamine turnover, 7
Receptor(s)
in cellular uptake of retinol, 972–975
proteolytic modification or degradation, calpain system in, 828
retinol-binding protein, 974–975
Reinforcement
dopaminergic transmission in, 195–204
place conditioning for determination of, 202–204
oxytocin and, 346
Renal artery
adenosine or bradykinin infusion, reflex effects on cardiovascular system and, 670–671
occlusion, reflex effects on cardiovascular system and, 669–670
pressure, reflex effects on cardiovascular system and, 669–670
Renal medullary cells
adaptation to hypertonicity, model of, 1093–1094
aldose reductase in, 1089
osmotically induced changes in, 1089–1091
organic osmolytes in, 1081–1109. *See also specific osmolytes*
beneficial effects, 1105–1108
betaine, 1097–1100
cellular permeability to different organic osmolytes and, 1104
correlation with sodium and urea in renal medulla, 1086
determinants of relative amounts, 1103–1105
effect of each organic osmolyte on accumulation of others, 1104–1105
glycerophosphorylcholine, 1094–1097
harmful effects, 1108–1109
inositol, 1100–1103
intrarenal distribution, 1083–1084
in vitro model systems, 1086–1087
levels relative to diuretic state, 1084–1086
magnitude of hypertonicity and, 1104
measurement of, 1082–1083
predominant compatible organic osmolytes, 1082
protection against hypertonicity, 1105–1197
protection against urea by counteracting organic osmolytes, 1107–1108
sorbitol, 1087–1094
taurine, 1103
toxicity of excessive sorbitol accumulation, 1108–1109
urea concentration and, 1103–1104
sorbitol dehydrogenase in, 1089
osmotically induced changes in, 1091
Renal nerves
anatomic evidence of renal afferent fibers, 660–662
anatomic localization of renal sensory neurons, 661–662
central projections of afferent fibers, 665–668
brain stem, 666–667
hypothalamus and limbic projections, 667
spinal cord, 665–666
in diuretic response to atrial distension, 634
effect of efferent on afferent activity, 665
electrical stimulation, reflex effects on cardiovascular system, 668–669
electrophysiological characteristics of afferent fibers, 664–665
electrophysiological evidence of renal receptors, 662–665
chemoreceptors, 663–664
mechanoreceptors, 662–663
functional role of renal afferents, 659–677
hypertension and, 676–677
reflex effects on cardiovascular system, 668–672
decreased renal artery pressure and renal artery occlusion and, 669–670
electrical stimulation and, 668–669
increased renal vein pressure and renal vein occlusion and, 669
increased ureteral pressure and, 670
intrarenal artery bradykinin or adenosine infusion and, 670–671
maneuvers applied to kidney and, 669–672
pelvic perfusion with concentrated urine and, 670
renal nerve section or blockade, 669
renorenal reflexes, 672–676. *See also* Renorenal reflexes
section or blockade, reflex effects on cardiovascular system, 669
Renal vein
occlusion
reflex effects on cardiovascular system and, 669
renorenal reflexes and, 674
pressure, reflex effects on cardiovascular system and, 669
Renin, in diuretic response to atrial distension, 633
Renorenal reflexes, 672–676
electrical stimulation of afferent renal nerves and, 673
electrophysiological evidence, 672–673
functional evidence, 673–676
hypertension and, 677
increased pelvic and ureteral pressure and, 674
intrapelvic perfusion with hyperosmotic solutions and, 674
intrarenal bradykinin or adenosine injection and, 674–675
renal vein occlusion and, 674
unilateral renal denervation and, 673–674
Reperfusion injury, cation transport and, 762–763
Research, dopamine, 155–156
Respiratory function, development of, at high altitudes, 1155–1156
Respiratory immunity
air-exchange surface, 1124–1130
cellular and noncellular components in bronchoalveolar lavage fluid, 1125
alveolar milieu, 1124–1130
alveolar space
immune interactions in, 1125–1128
immune responsiveness in, 1128–1130
immunologic components in conducting airways, 1118–1124
antigen-presenting cells, 1122–1124
lymphoid tissue, 1120–1122
secretory immunoglobulins, 1119–1120
integrated immunologic function of airways, 1124
topography of airways, 1117–1118
Respiratory tract
antigen-presenting cells in, 1122–1124
immunologic system in, 1117. *See also* Respiratory immunity
lymphoid tissue in, 1120–1122
topography of airways, 1117–1118
Retina
amacrine cells, 456–462
amacrine cell coverage, 462
γ-aminobutyric acid-ergic, 459
cholinergic amacrine cells and directional selectivity, 457–459
conservation of amacrine cell shape, 460–462
definition and functional polarity, 459–460
diversity, 456–457
glycinergic, 457

bipolar cells, 454–456
cone bipolar cells and on- and off-dichotomy of retina, 454
rod bipolar circuitry, 455–456
types of cone bipolar cells, 454–455
functional architecture, 447–471
ganglion cells, 463–471
density and cortical magnification factor, 470–471
function, 468–471
ganglion cell coverage, 465–468
microcircuitry, 468
morphological classes, 464
physiological classes, 463–464
spatial resolution, 468–470
stimulus detection, 470
stratification of ganglion cell dendrites, 464–465
horizontal cells, 451–454
photoreceptors and spatial sampling, 449–451
topography, 448–449
Retinoic acid, plasma retinol homeostasis and, 978–980
Retinol. *See* Vitamin A
Retinol-binding protein
iodinated, saturable binding to plasma membranes, 973
modification by binding to its receptor, 974
receptor, 974–975
retinol bound to. *See* Retinol transport complex
selective interaction with specific cell types, 972–973
type II, cellular, in retinol absorption, 955–956
Retinol recycling, 975–978
early indications, 975
from extrahepatic tissues, 977
model-base compartmental analysis to quantify, 975–976
between plasma and liver, 976–977
speculations about, 977–978
Retinol transport complex
binding to receptor, transthyretin and, 974
plasma, uptake by liver cells, 968
Ribonucleic acid (RNA)
in compensatory overload-induced hypertrophy, 563–564
export from nucleus, 931–934
anchorage of RNA to nuclear matrix, 931
nuclear pore complex in, 931
nuclear substructures in, 934
nucleosidetriphosphatase in, 931
RNA structural features required for, 931–934
messenger
in compensatory overload-induced hypertrophy, 564
skeletal muscle adaptation to aerobic training, 548

S

Salivary glands, vertebrate, acetylcholine and vasoactive intestinal peptide in, 702–703
Sarcolemma, cardiac, exercise training and, 571
Sarcomere, cardiac, uniformity, 417–418
Sarcoplasmic reticulum
cardiac, exercise training and, 571–572
skeletal muscle, single bout of exercise and, 547
Self-inhibition, apical sodium entry in epithelia, 430–431
pharmacology of, 436–437
Self-stimulation
control, histaminergic neurons in, 29
dopaminergic transmission and, 196–198
Sensitization phenomenon. *See* Behavioral sensitization
Sensorimotor integration, dopaminergic transmission and, 160
Septal system, dopaminergic transmission, 166–168
Sexual behavior
female, oxytocin and, 342–343
male, oxytocin and, 342
Sexual tract, dilation, oxytocin and, 344
Skeletal muscle
atrophy, regrowth, 565–566
catecholamine regulation of calcium transport, 753
comparative elastic properties of skeletal and cardiac cells, 415
energy requirement of calcium transport, 742–745
during contraction, 743–745
at rest, 742–743
energy requirement of sodium-potassium transport, 734–736
excitation-contraction coupling. *See also* Excitation-contraction coupling
voltage sensor of, 849–898
fatigue during exercise, 542–544
adenosine triphosphate depletion and, 542
glycogen depletion and, 542–543
insufficient skeletal muscle mass and, 544
limited maximal oxygen flux and, 543–544
mitochondrial adaptation and, 553
pH and, 542
heavy sarcoplasmic reticulum, 885
hypertrophy
adaptations differ between certain animal models and humans, 561–562
in animal models not mimicking human physical activity, 561–564
compensatory overload-induced, animal models, 563–564
stretch-induced, animal models, 562–563
molecular and cellular adaptation to exercise, 541–566
aerobic vs. strength training, 561
glucose uptake, 545–547
glycolytic enzymes, 553–555
hypertrophy in animal models not mimicking human physical activity, 561–564
inferred sites for gene expression in animal models that closely mimic human physical activity, 566
lactate dehydrogenase, 555–556
malonyl-coenzyme A, 547
mitochondrial adaptations, 547–553
models closely mimicking human physical activity, 544
models of increased contractile activity that do not mimic human physical activity, 544–545
muscle/muscle cells in culture do not mimic human physical activity, 564–565
myosin isoform switching, 556–559
oxygen flux, 559–560
physiological significance, 541–542
repeated bouts of aerobic exercise, 547–560
repeated bouts of resistance exercise, 560–561
response to single bout of exercise, 545–547
sarcoplasmic reticulum, 547
subcellular fractionation studies, 885–886
thyroid hormone regulation of calcium transport, 753–756
thyroid hormone regulation of sodium-potassium transport, 749–750
T-tubule membrane vesicles, 886
Sleep, control, histaminergic neurons in, 27–29
Sleep-wake rhythm, oxytocin and, 340–341
Smooth muscle
adenosine triphosphate as cotransmitter in, 687
cellular proliferation, glycosaminoglycans and, 507–512
cotransmission in, 697–700
energy requirement of sodium-potassium transport, 741
Sodium
extracellular, cellular recognition of changes in, 401–402
glucose absorption and, in fetal lung, 1006–1007
Sodium channels
activation kinetics, 1052–1062
activation as multistep process, 1052–1055
are gating models based on subunits tenable, 1057

limitations of Hodgkin and Huxley activation model, 1055–1057
subunit model for, 1057–1062
in B cells, 801
gating current, 883–885
voltage-dependent inactivation, 883–885
inactivation as a separable process, 1062–1070
can inactivation proceed without activation, 1065
inactivation and activation are not independent, 1063–1065
inactivation can also have multiple time constants, 1069–1070
modeling the inactivation process, 1065–1069
removal of inactivation leaves activation kinetics unaltered, 1062–1063
slow and fast inactivation are separate processes, 1070
voltage dependence of return from inactivation, 1065
kinetic measurement and modeling
action potentials, 1050
gating currents, 1050
mean currents under voltage clamp, 1050
methods of kinetic modeling, 1051
single-channel recordings, 1050–1051
molecular kinetics, 1047–1076
activation kinetics, 1052–1062
basic kinetic behavior, 1051–1052
contraints of reality imposed on ideal kinetics, 1071–1074
homologies to calcium and potassium channels, 1075–1076
inactivation as a separable process, 1062–1070
limitations of present models and future directions, 1070–1071
methods of kinetic measurement and modeling, 1050–1051
relation to other voltage-dependent channels, 1074–1076
variability in kinetics between channels with different structures, 1072
variability in kinetics intrinsic to single channels, 1072–1073
variability in permeation properties of open channels, 1073–1074
molecular structure, 1048–1050
development of a molecular perspective, 1048
primary structure, 1049–1050
structural homologies to calcium and potassium channels, 1075
in T cells, 794
Sodium transport. *See also* Cation transport; Principal cells
across alveolar epithelia of adult lungs, 1009
apical sodium entry in epithelia, intrinsic regulation of, 429–440
renal collecting duct, 271–272
sodium conductive pathways in mitochondria-rich cells, 247
Somatosensory compensation, visual deprivation and, 596
Somatostatin
acetylcholine and, in parasympathetic control of toad heart, 700
inhibitory actions, 1036
localization, 1036
neurotrophic actions, 1036
Sorbitol
accumulation in renal cells
osmotic induction of, 1089
toxicity of excessive accumulation, 1108–1109
model of renal medullary cell adaptation to hypertonicity, 1093–1094
physiological roles, 1087
relation between renal medullary sodium, sorbitol, and aldose reductase in vivo, 1093
renal cell permeability to, rapid changes in, 1091–1092
synthesis and degradation, 11087–1089
Sorbitol dehydrogenase, 1088–1089
in renal cells, 1089
osmotically induced changes in, 1091
Spatial memory, dopaminergic transmission and, 167–168
Spinal cord
afferent renal nerve fiber projections, 665–666
target areas for oxytocin and action mechanisms, 351–352
Stereotyped behavior, oxytocin and, 344–345
Stereotypy, dopaminergic neuron activation and, 172–176
Stress
baroreceptor reflex response, 317–318
cardiovascular response to, 305–326. *See also* Cardiovascular system
control, histaminergic neurons in, 29
dopaminergic transmission and, 163–164
epinephrine kinetics and, 318–319
hyperthermia and, 117
neuroendocrine response, 318–323
methodological issues in measuring, 322–323
neuropeptides in, 321–322
norepinephrine kinetics and, 318
pituitary-adrenal responses, 319–321
renal blood flow and, 313–316
sympathetic nerve activity and, 316–317
Stress hormones, 305–306
Substance P
interaction with thyrotropin-releasing hormone, 1033
localization and coexistence with other neuropeptides, 1034
motor effects, 1035
possible opposing effects on neuronal regeneration, 1035
sensory effects, 1034–1035
Sulfhydryl oxidants, skeletal muscle excitation-contraction coupling and, 882
Sulfhydryl oxidation, in excitation-contraction coupling, 892

T

T cells
calcium conductances in, 794–795
chloride conductances, 795–796
ion channels in, 788–799
physiological relevance of ionic conductances in, 796–799
potassium conductances in, 788–794
antagonists, 791–792
calcium-activated, 793–794
L-type, 793
N-type, 789–793
outward voltage-gated, 788–793
response to mitogens
calcium channels and, 797–798
potassium channels and, 797
sodium conductance, 794
Tachykinins, calcitonin gene-related peptide and, in mammalian heart and other peripheral sites, 698–700
Talin, cleavage in platelet aggregation, calpain system and, 829
Tamponade, cardiac reflexes and, 631
Target cells, in neuronal development and regeneration, 1022–1023
specific neurotrophic factors in, 1023
time-dependent relationships between neurons and target cells, 1022–1023
Taurine, in renal medullary cells, 1103
Temperature
potassium conductance in T cells and, 791
rhythmicity of embryonic heart and, 66–67
Thermogenesis, cation transport and basal metabolic rate and, 757–759. *See also* Cation transport
cold adaptation, 758
endothermia, 758–759
sodium-potassium pump-dependent oxygen uptake in intact organism, 757–758
Thermoregulation
histaminergic neurons in, 26–27
oxytocin and, 339–340

Thrombospondin, glycosaminoglycan interactions, 504
Thyroid hormones
calcium transport and, 753–757
heart, 756–757
skeletal muscle, 753–756
epinephrine-induced fetal lung liquid reabsorption and, 1003–1004
gestational pattern of plasma levels, 1003
sodium-potassium transport and, 749–752
heart, 750–751
intestine and fat cells, 752
kidney, 751–752
liver, 751
skeletal muscle, 749–750
Thyrotropin, secretion, histaminergic neurons and, 24
Thyrotropin-releasing hormone (TRH)
electrophysiological actions, 1033
gender-specific action, 1034
interaction with 5-hydroxytryptamine, 1033
interaction with opiates, 1033
interaction with substance P, 1033
localization and coexistence with other neuropeptides, 1032–1033
mechanism of neurotrophic action, 1033–1034
neurotrophic effects, 1033
Tissue capillarity, oxygen diffusion from blood to tissue and, in physiological adaptation to high altitude, 1149–1150
Tolerance
dopaminergic transmission and, 195
oxytocin and, 346–347
Transcription factors, glycosaminoglycan interactions, 506–507, 521–522
Transthyretin, binding of retinol-retinol-binding protein to receptor and, 974
Triiodothyronine. *See also* Thyroid hormones
effect on development of epinephrine-induced fetal lung liquid reabsorptive response, 1004
Tuberomamillary nucleus, histaminergic perikarya in, 9–10
Tumor(s), growth, angiogenesis, and metastasis, glycosaminoglycans and, 515–518
Tumor necrosis factor, fever and, 106–107, 114

U

Urea, protection against, counteracting organic osmolytes and, 1107–1108
Urea concentration, organic osmolyte accumulation in renal medullary cells and, 1103–1104
Ureteral pressure, increased
reflex effects on cardiovascular system and, 670
renorenal reflexes and, 674
Urinary bladder, vertebrate, chloride transport, 266–271
Urine
flow, atrial distension and, 631–632
putative endogenous antipyretics in, 112–114
Uromodulin, interleukin 1 inhibition, 113

V

Vagus nerve(s)
afferent activity ending in ventricles, 621–624
myelinated afferent fibers attached to atrial receptors, 619–621
nonmyelinated afferent fibers arising from atria, 621
Vascular system
atrial receptor stimulation and, 629–630
ventricular receptor stimulation and, 639–640
Vas deferens, cotransmission, 697–698
Vasoactive intestinal peptide, acetylcholine and, in vertebrate salivary glands, 702–703
Vasopressin
cotransmitter function, 708
fetal lung liquid secretion and, 1007
in posterior pituitary, 709
release, corticotropin-releasing factor and, 708–709
Ventilation, pulmonary, initiation of, fetal lung liquid reabsorption and, 1007–1008
Ventilatory response, high altitude and, 1137–1139
Ventral mesencephalic tegmentum, dopaminergic cell bodies and, 158–160. *See also* Dopaminergic network (neurons)
Ventral striatum system, dopaminergic transmission, 161–162
Ventricle(s), cardiac, afferent activity in vagal nerves ending in, 621–624
Vigilance, control, histaminergic neurons in, 27–29
Visual acuity, ganglion cells in, 468–471
Visual plasticity, 587–605
compensatory plasticity after visual deprivation, 594–596
human studies, 596
multimodal competition, 595–596
somatosensory compensation, 596
transitory connections, 595
visual-auditory interactions, 596
cortical plasticity
gating substances and chemical markers for, 604
limbic system in, 604
norepinephrine hypothesis, 603–604
unspecific modulatory systems influencing rate of consolidation in, 603–605
plasticity of binocular interactions in cats and monkeys, 588–592
binocular deprivation and competition, 589
effects of squint and neural basis of amblyopia, 589–592
eye-closure experiments and binocular competition, 588–589
loss of binocularity in striate cortex, 590
monocular deprivation and recovery, 588–589
neural basis of strabismic amblyopia, 590–592
plasticity of feature selectivity in visual cortex, 592–594
determinants of sensitive periods, 593–594
direction selectivity, 592–593
orientation selectivity, 592
synaptic plasticity, 596–605
activity dependence of changes in cortical circuitry, 596–601
cellular and molecular neuroanatomy of plastic changes, 603
consolidation of synaptic changes, possible biochemical cascades, 601–603
dunamics of synaptic consolidation, 602–603
Hebb's postulate, 596–598
N-methyl-D-aspartate receptor hypothesis, 598–601
molecular events mediating synaptic modification, 601–602
unspecific modulatory systems influencing rate of consolidation in cortical plasticity, 603–605
Vitamin A
delivery to and uptake by cells, 970–975
characterization of retinol-binding protein receptor, 974–975
fluid phase endocytosis, 971–972
in vitro studies of cellular uptake, 973–974
is retinol-binding protein modified by binding to its receptor, 974
partitioning of unbound retinol into plasma membrane, 971
processing after delivery to target cells, 975
receptor involvement in, 972–975
saturable binding of iodinated retinol-binding protein to plasma membranes, 973

selective interaction of retinol-binding protein with specific cell types, 972–973
transthyretin and binding of retinol-retinol-binding protein to receptor, 974
esterification
in enterocytes, 956–958
in liver, 965–966
in liver, 961
metabolism. *See* Vitamin A metabolism
preformed, 954–955
processing after delivery to target cells, 975
provitamin A, 954
retinol-binding protein-bound. *See also* Retinol transport complex
dynamics of turnover and recycling, 975–978. *See also* Retinol recycling
Vitamin A homeostasis, plasma, 978–982
blood pressure regulation and, 982
experimental observations, 978–980
kidney disease and, 980
liver in, 978
plasma retinol output and, 980–981
possible dependence of vitamin A utilization rate on plasma retinol level, 981–982
retinoic acid and *N*-(4-hydroxyphenyl)retinamide in, 978–980
Vitamin A metabolism, 951–983
intestinal absorption, 954–961
cellular retinol-binding protein type II in, 955–956
esterification of retinol in enterocytes, 956–958
extrahepatic clearance of chylomicron retinyl esters, 960–961
plasma metabolism of chylomicrons, 958–959
processing of dietary vitamin A, 954–955
use of chylomicron retinyl esters to study chylomicron metabolism, 959–960
liver in, 961–970
esterification of retinol, 965–966
hepatic cell types, 961–962
mechanism for transfer of retinol from parenchymal to stellate cells, 964–965
mobilization of retinol from, 966–968
processing of chylomicron remnant retinyl esters by parenchymal cells, 962–963
speculations about transport and storage of retinol in hepatic cells, 969–970
storage of retinyl esters in stellate cells, 965
transfer of diet-derived retinol from parenchymal to stellate cells, 963–964
uptake of chylomicron remnant retinyl esters by parenchymal cells, 962
uptake of plasma retinol-retinol-binding protein by liver cells, 968
overview, 952–954
recycling. *See* Retinol recycling
Vitronectin, glycosaminoglycan interactions, 502–503
Voltage sensor, skeletal muscle excitation-contraction coupling and. *See* Excitation-contraction coupling

W

Wakefulness, control, histaminergic neurons in, 27–29
Water immersion, cardiac reflexes and, 631